Skip to main content

Table 4 Median serum levels of the selected cytokines at different time point in participants with and without preventive treatment respectively

From: Serum level of IL-1ra was associated with the treatment of latent tuberculosis infection in a Chinese population

aCytokine

Active TB

Non-TB

T0

T1

p for Wilcoxon signed rank test

T0

T1

p for Wilcoxon signed rank test

Median value (Q25-Q75) (pg/ml) in treated participants (active TB, n = 12; non-TB, n = 24)

 Eotaxin

69.18 (58.08, 87.05)

45.18 (36.09,75.64)

0.021

37.14 (26.61, 66.58)

33.34 (22.22, 48.22)

0.010

 MCP-1(MCAF)

14.08 (10.57, 20.05)

11.60 (9.68, 15.26)

0.052

7.91 (5.65, 10.10)

7.38 (5.01, 12.86)

0.300

 MIP-1β

50.75 (47.05, 63.37)

56.63 (50.95, 61.09)

0.470

38.06 (30.83, 44.48)

49.03 (44.11, 54.68)

< 0.001

 SDF-1α

309.99 (234.09, 339.68)

229.56 (203.70, 261.91)

0.007

211.88 (190.64, 251.72)

177.85 (158.87, 220.24)

0.008

 G-CSF

89.49 (73.15, 97.55)

71.50 (60.18, 85.92)

0.110

49.40 (36.56, 62.44)

65.14 (39.89, 78.41)

0.040

 VEGF-A

46.18 (38.72, 62.85)

42.22 (28.75, 52.27)

0.339

13.34 (3.37, 23.12)

6.43 (0.25, 37.39)

0.187

 Basic FGF

23.62 (20.22, 25.25)

19.51 (18.79, 21.27)

0.010

11.60 (7.52, 17.13)

11.28 (6.52, 20.05)

0.459

 IFN-γ

20.89 (17.76, 33.82)

19.74 (12.71, 26.54)

0.021

14.41 (9.16, 16.86)

13.87 (5.52, 16.82)

0.320

 TNF-α

15.89 (14.22, 17.78)

15.41 (12.66, 17.78)

0.349

8.97 (7.94, 12.41)

10.36 (6.77, 13.98)

0.478

 TRAIL

40.94 (35.11, 44.48)

36.59 (36.42, 43.32)

0.733

32.11 (30.12, 38.04)

31.28 (23.18, 37.34)

0.037

 IL-1α

16.45 (11.86, 22.98)

13.01 (10.72, 14.53)

0.015

5.51 (3.21, 7.47)

5.24 (1.52, 14.53)

0.129

 IL-1ra

173.64 (157.39, 185.69)

126.44 (114.19, 133.83)

0.002

107.36 (80.87, 150.82)

95.66 (55.77, 131.74)

0.009

 IL-4

2.34 (1.94, 3.01)

1.61 (1.36, 2.01)

0.013

0.52 (0.39, 1.42)

0.64 (0.04, 1.55)

0.575

 IL-8

6.04 (4.40, 7.19)

4.05 (3.58, 4.64)

0.017

3.14 (2.15, 4.36)

2.04 (0.70, 3.34)

< 0.001

 IL-9

65.00 (53.56, 69.74)

63.83 (55.94, 77.15)

0.733

30.86 (24.88, 41.36)

37.00 (31.20, 64.25)

< 0.001

 IL-17A

6.68 (6.05, 8.09)

5.74 (5.05, 6.21)

0.034

3.90 (2.39, 5.12)

2.97 (0.57, 5.90)

0.187

Median value (Q25-Q75) (pg/ml) in untreated controls (active TB, n = 9; non-TB, n = 18)

 Eotaxin

86.14 (56.31, 100.06)

55.38 (39.96, 59.73)

0.012

34.46 (29.40, 37.82)

28.43 (21.67, 38.27)

0.265

 MCP-1(MCAF)

12.60 (9.20, 16.31)

12.17 (11.41, 14.12)

0.570

6.81 (5.14, 9.74)

6.88 (5.14, 10.16)

0.212

 MIP-1β

48.10 (38.42, 57.29)

57.68 (49.97, 59.57)

0.301

38.03 (33.57, 43.83)

48.19 (35.40, 54.16)

0.024

 SDF-1α

268.74 (253.62, 357.07)

223.75 (205.00, 256.94)

0.039

219.86 (181.17, 275.33)

175.13 (142.03, 225.55)

0.027

 G-CSF

70.18 (68.86, 89.17)

78.74 (64.20, 94.98)

0.820

45.96 (39.89, 52.46)

52.17 (32.71, 62.19)

0.304

VEGF-A

30.46 (19.20, 52.30)

27.04 (14.41, 35.17)

0.496

10.62 (3.37, 15.07)

13.88 (0.25, 27.04)

0.426

Basic FGF

19.51 (19.51, 27.46)

19.51 (18.06, 20.92)

0.055

9.91 (7.71, 11.27)

11.98 (6.93, 15.78)

0.186

IFN-γ

26.08 (18.59,31.97)

20.47 (14.40,26.28)

0.055

9.48 (8.21, 14.39)

9.52 (4.75, 15.24)

0.702

TNF-α

13.98 (12.53,16.84)

14.46 (11.81,16.84)

0.688

9.60 (6.47,13.04)

9.00 (5.07, 11.08)

0.246

TRAIL

35.54 (34.96,55.72)

40.35 (38.76,42.93)

0.820

28.38 (20.62, 33.46)

25.86 (18.61, 32.15)

0.694

IL-1α

9.96 (8.44, 11.48)

11.48 (7.68, 14.53)

0.742

4.23 (1.86, 4.92)

4.32 (1.52,9.96)

0.096

IL-1ra

164.78 (145.93, 185.71)

116.49 (111.89, 129.64)

0.078

70.70 (55.80, 128.01)

89.36 (40.01, 109.54)

0.265

IL-4

2.18 (2.01, 2.59)

1.67 (1.42, 1.87)

0.027

0.35 (0.17, 0.51)

0.58 (0.05, 1.16)

0.072

IL-8

4.75 (3.46, 6.61)

3.81 (3.22, 4.05)

0.047

2.28 (1.57, 3.16)

1.91 (0.84, 2.39)

0.030

IL-9

58.55 (51.44, 65.08)

66.41 (58.89, 69.24)

0.496

29.50 (26.06, 32.90)

35.55 (23.97, 64.91)

0.003

IL-17A

5.12 (4.50, 5.90)

5.43 (4.50, 6.05)

0.578

2.47 (1.16, 3.73)

3.12 (1.16, 4.19)

0.832

  1. Abbreviation: T0 baseline, T1 At the end of preventive treatment; Q25 25% quantile, Q75 75% quantile, TB tuberculosis
  2. a Those cytokines, which had a significantly higher level in active TB individuals compared with non-TB controls at T0 were selected